VBC 103
Alternative Names: VBC-103Latest Information Update: 26 Nov 2024
At a glance
- Originator VelaVigo (Shanghai) Limited
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Nov 2024 VelaVigo announces the intention to submit an Investigational New Drug application for Solid tumours to the US FDA in 2025
- 18 Nov 2024 VelaVigo announces the intention to submit an Investigational New Drug application for Solid tumours to the Chinese National Medical Products Administration (NMPA) in 2025
- 18 Nov 2024 Avenzo Therapeutics and VelaVigo agree to co-develop VBC 103 in worldwide excluding China for Solid tumours